and/or

20 News Items found

Feature

How a Chicken Helped Solve the Mystery of Cancer

When this feathered patient found her way into a New York laboratory in 1909, she changed the course of cancer science.

A barred Plymouth Rock hen

In the Clinic

Genetic ‘Scars’ Provide Clues for Tailoring Cancer Treatment

For the first time, scientists have determined the extent of DNA repair deficiencies across cancer types. Learn what it means for patients.

Image of DNA helix with sequence in the background

Announcement

FDA Approves Enasidenib (Idhifa), a First-of-Its-Kind Drug, for Advanced Blood Cancer

A new treatment option for people with acute myeloid leukemia is available, and it works in an unconventional way.

Acute myeloid leukemia cells under a microscope

In the Lab

Giving Drugs Together — Rather than in Sequence — May Be Key to Halting Tumor Resistance

Scientists are learning how tumors develop resistance to drugs — and what can be done about it.

Representative image of a dividing tumor cell showing the extrachromosomal location of duplicated BRAF genes

In the News

#ASCO17: Post-Conference Roundup of Themes and Trends

Read up on the progress being made in several key areas of cancer research, including immunotherapy, targeted therapy, precision surgery, and epigenetics.

American Society of Clinical Oncology logo

Feature

With MSK Leading the Way, Precision Medicine Links Lab Research to Patient Care

Therapies that target genetic alterations in tumors are showing promise for many cancer patients, but challenges in developing these new treatments remain.

Decoder

What Are Exceptional Responders?

When a clinical trial of a new drug fails because most patients don’t respond, progress can still be made by analyzing the tumors of the rare patients who benefit.

Exceptional responders of new drugs in clinical trials.

In the Clinic

The Evolution of a Lifesaving Drug: A Scientist Reflects

Physician-scientist Charles Sawyers played a pivotal role in the development of Gleevec, one of the first successful targeted drugs for cancer.

Pictured: Charles Sawyers

In the Clinic

Report Highlights Advances Made at MSK That Are Changing Patients’ Lives

An annual report from an influential cancer group highlights three MSK studies that have advanced cancer research.

Finding

Study Reveals How Some Breast Cancers Become Resistant to Targeted Drugs

A study of one patient’s disease has clarified why tumors stop responding to a class of experimental drugs called PI3K inhibitors.

(From left) MSK investigators Michael Berger, José Baselga, and Maurizio Scaltriti, and graduate student Pau Castel.